Salarius Pharmaceuticals, INC 8-K filings
8-K: Salarius Pharmaceuticals Secures Conditional Nasdaq Listing Extension Amidst Compliance Challenges
Salarius Pharmaceuticals, Inc. has been granted a conditional extension by the Nasdaq Hearings Panel to regain compliance with minimum bid price and stockholders' equity requirements, avoiding immediate delisting.
Salarius Pharmaceuticals, Inc. has announced a second amendment to its merger agreement with Decoy Therapeutics Inc., drastically reducing Salarius's relative valuation and increasing Decoy's post-merger ownership due to a substantial decline in Salarius's stock price.
Salarius Pharmaceuticals receives notice from Nasdaq regarding non-compliance with minimum bid price and equity standards, potentially leading to delisting.
Salarius Pharmaceuticals amends its merger agreement with Decoy Therapeutics, fixing ownership percentages and addressing a Nasdaq listing deficiency due to insufficient stockholders' equity.
Salarius Pharmaceuticals announces the filing of a prospectus supplement related to its existing at-the-market offering agreement to sell up to $417,000 of common stock.
Salarius Pharmaceuticals disclosed a preliminary cash balance of $2.4 million as of December 31, 2024, and completed the sale of 141,000 shares of common stock for $493,500.
Salarius Pharmaceuticals and Decoy Therapeutics have signed a definitive merger agreement to combine their businesses, leveraging Decoys peptide conjugate drug design platform.
Salarius Pharmaceuticals successfully held its 2024 Annual Meeting, re-electing two Class III directors, approving executive compensation, and ratifying Ernst & Young as its auditor.
Salarius Pharmaceuticals has entered into a securities purchase agreement with C/M Capital Master Fund for up to $10 million in newly issued shares of common stock.
Salarius Pharmaceuticals has announced the date for its 2024 Annual Meeting of Stockholders as December 20, 2024, and has established deadlines for shareholder proposals and director nominations.
Salarius Pharmaceuticals believes it has regained compliance with Nasdaq's minimum stockholder equity requirement after a recent stock sale, though continued monitoring is required.
Salarius Pharmaceuticals has filed a prospectus supplement for a registered offering of up to $335,921 of its common stock.
Salarius Pharmaceuticals has filed a prospectus supplement for an at-the-market offering of up to $335,921 of its common stock.
Salarius Pharmaceuticals has filed a prospectus supplement for an offering of up to $810,973 of its common stock.
Salarius Pharmaceuticals is closing its Phase 1/2 clinical trial for seclidemstat in Ewing sarcoma to conserve cash while exploring strategic alternatives.
Salarius Pharmaceuticals' clinical trial for seclidemstat in combination with azacitidine has been placed on partial clinical hold by the FDA after a patient experienced a serious adverse event.
Salarius Pharmaceuticals reported a 43% overall response rate in a Phase 1/2 study of seclidemstat combined with azacitidine for patients with myelodysplastic syndrome and chronic myelomonocytic leukemia who had previously failed other treatments.
Salarius Pharmaceuticals has executed a 1-for-8 reverse stock split to meet Nasdaq's minimum bid price requirement, effective June 14, 2024.
Salarius Pharmaceuticals has received an extension from Nasdaq until September 3, 2024, to regain compliance with the minimum bid price rule.
Salarius Pharmaceuticals is implementing cost-saving measures, including transitioning its CEO to a consultant role, to extend its cash runway into the first half of 2025 and support ongoing clinical trials.